Lexeo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||||
| Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||||
| Shares · Amount · Stock · Capital · Income (Loss) · Deficit · Equity | ||||||||
| Balances at December 31, 2024 | 33,071,261 | $3 | $(17) | $397,132 | $(103) | $(280,173) | $116,842 | |
| Exercise of stock options | 15,300 | - | - | 59 | - | - | 59 | |
| Issuance of common stock upon vesting and settlement of restricted stock units | 101,448 | - | - | - | - | - | - | |
| Issuance of common stock upon vesting and settlement of performance restricted stock units | 76,800 | - | ||||||
| Issuance of common stock under 2023 ESPP | 102,837 | - | - | 270 | - | - | 270 | |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | 7,532 | - | - | 37 | - | - | 37 | |
| Issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement, net of commissions and offering costs of $6,917 | 20,790,120 | 2 | - | 73,080 | - | - | 73,082 | |
| Issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions, net of commissions and offering costs of $9,833 | 17,968,750 | 2 | - | 143,915 | - | - | 143,917 | |
| Issuance of common stock upon exercise of pre-funded warrants | 867,302 | - | - | - | - | - | - | |
| Unrealized comprehensive gain on investments in U.S. Treasury securities | - | - | - | - | 291 | - | 291 | |
| Stock-based compensation expense | - | - | - | 12,132 | - | - | 12,132 | |
| Net loss | - | - | - | - | - | (99,961) | (99,961) | |
| Balances at December 31, 2025 | 73,001,350 | 7 | (17) | 626,625 | 188 | (380,134) | 246,669 | |
| Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||
| Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||
| Shares · Amount · Stock · Capital · Income (Loss) · Deficit · Equity | |||||||||
| Balances at December 31, 2023 | 26,646,378 | $3 | $ | - | $295,372 | $ | - | $(181,840) | $113,535 |
| Exercise of stock options | 135,646 | - | - | 491 | - | - | 491 | ||
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | 14,159 | - | - | 59 | - | - | 59 | ||
| Issuance of common stock upon March 2024 Private Placement, net of commissions and offering costs of $6,287 | 6,278,905 | - | - | 88,712 | - | - | 88,712 | ||
| Additional issuance costs incurred related to issuance of convertible SAFE Note | (3,827) | - | - | 24 | - | - | 24 | ||
| Treasury stock repurchase | - | - | (17) | - | - | - | (17) | ||
| Unrealized comprehensive loss on investments in U.S. Treasury securities | - | - | - | - | (103) | - | (103) | ||
| Stock-based compensation expense | - | - | - | 12,474 | - | - | 12,474 | ||
| Net loss | - | - | - | - | - | (98,333) | (98,333) | ||
| Balances at December 31, 2024 | 33,071,261 | $3 | $(17) | $397,132 | $(103) | $(280,173) | $116,842 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.